Pediatrics:大剂量鱼油不能预防婴幼儿过敏

2012-09-28 网络 网络

        一项随机对照试验研究发现,在出生后至6个月期间,给婴儿服用相对大剂量的鱼油可以适度地提高他们体内的n-3多不饱和脂肪酸(n-3 PUFAs)水平,但是并不能预防他们发生儿童变态反应性疾病。     Western Australia大学儿科与儿童卫生学院的N. D'Vaz及其合着者将研究

   

    一项随机对照试验研究发现,在出生后至6个月期间,给婴儿服用相对大剂量的鱼油可以适度地提高他们体内的n-3多不饱和脂肪酸(n-3 PUFAs)水平,但是并不能预防他们发生儿童变态反应性疾病。

    Western Australia大学儿科与儿童卫生学院的N. D'Vaz及其合着者将研究成果发表于9月3日Pediatrics杂志在线版上。许多变态反应性疾病的流行与西方生活方式的改变有关,然而要检测出其中特定环境因素的影响是非常困难的。有人敏锐的注意到了膳食中n-3多不饱和脂肪酸(n-3 PUFAs)的减少与n-6多不饱和脂肪酸(n-6 PUFAs)的增加,因此认为饮食结构的改变是其中一个主要因素。

    研究者通过观察性研究以及介入性研究发现,于孕妇膳食中补充鱼油可以预防婴幼儿过敏。D'Vaz及其同事探索了给予6个月内婴儿服用鱼油是否也会产生相预防效果。

    2005年1月6日至2008年1月10日期间,他们从城市内的私人和公立的产前诊所内招募了420名孕期为36周的志愿者。这些孕妇的入选条件是有过敏史,很少摄食鱼类并且无吸烟史。将其随机分为两组,试验组218名,对照组202名。实验组婴儿从出生后起,每日在清晨的第一次喂奶前,用胶囊于口中挤入650mg鱼油。使用同样方法,每日给予对照组婴儿650mg橄榄油。

    因为某品牌鱼油的供应中断,最后有27名婴儿服用了不同生产商的同类胶囊。在干预期结束时,这些婴儿与试验组其他婴儿的红细胞二十二碳六烯酸(DHA)和二十碳五烯酸(EPA)水平并无显着差异。

    研究者在婴儿们6个月时及12个月时对其进行评价,并且在相同的时间段内收集有关呼吸系统症状的信息,例如反复发作的喘息、哮喘、鼻炎等。

    作者这样写道:在干预期结束时,试验组红细胞及血浆DHA (P = .03) 和EPA (P = .016)水平显着高于对照组。然而在婴儿们12个月随访时,试验组与对照组间,那些变态反应性疾病、致敏(广泛或特异性的)、湿疹或食物过敏的发生并无显着差异。

    该研究小组写道:williamhill asia 的研究结果显示,虽然在6个月时,鱼油干预对婴儿的免疫系统具有潜在的有益效果。然而它并不能减少婴儿在其生命最初12个月内变态反应性疾病的发生。该结果与另一项先期研究的发现相符,即给予6个月以上婴儿鱼油对减少过敏的发生无效。

    本试验局限性包括依从性差。有62名参与者在研究结束前退出和/或不愿接受随访。脱落者中,鱼油组18.3%的脱落率显着高于安慰剂组10.9%的脱落率(P = .031)。即使给两种胶囊都添加了香草味,依然有92.2%的家长正确猜测出他们的孩子在鱼油组中。

    此外,尽管研究中使用了相对大剂量的n-3多不饱和脂肪酸(n-3 PUFAs),记录的婴儿体内n-3 PUFAs水平只有适度的增长,这表明所补充乙酯的吸收与生物利用度存在问题。最后,橄榄油可能并不是最佳的对照物,因为它也有一定的免疫调节效果。

    作者总结道:通过孕期与产后的对比,出现了更多关于长链多不饱和脂肪酸(l-c PUFA)具有抗过敏效果的证据,据此williamhill asia 建议,优化n-3 PUFAs状况依然是合适的,但最好通过促进母亲孕期与哺乳期间n-3 PUFAs的摄入来实现。

  链接:

D'Vaz N, Meldrum SJ, Dunstan JA, Martino D, McCarthy S, Metcalfe J, Tulic MK, Mori TA, Prescott SL.Postnatal Fish Oil Supplementation in High-Risk Infants to Prevent Allergy: Randomized Controlled Trial.Pediatrics.2012 Sep 3

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958368, encodeId=c337195836804, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jun 20 07:24:00 CST 2013, time=2013-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636576, encodeId=2cc116365e65b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 08 17:24:00 CST 2012, time=2012-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725454, encodeId=b1aa1e2545455, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 17 22:24:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578640, encodeId=d69615e864080, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Sep 30 05:24:00 CST 2012, time=2012-09-30, status=1, ipAttribution=)]
    2013-06-20 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958368, encodeId=c337195836804, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jun 20 07:24:00 CST 2013, time=2013-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636576, encodeId=2cc116365e65b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 08 17:24:00 CST 2012, time=2012-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725454, encodeId=b1aa1e2545455, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 17 22:24:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578640, encodeId=d69615e864080, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Sep 30 05:24:00 CST 2012, time=2012-09-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958368, encodeId=c337195836804, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jun 20 07:24:00 CST 2013, time=2013-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636576, encodeId=2cc116365e65b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 08 17:24:00 CST 2012, time=2012-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725454, encodeId=b1aa1e2545455, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 17 22:24:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578640, encodeId=d69615e864080, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Sep 30 05:24:00 CST 2012, time=2012-09-30, status=1, ipAttribution=)]
    2013-07-17 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958368, encodeId=c337195836804, content=<a href='/topic/show?id=766713993a1' target=_blank style='color:#2F92EE;'>#Pediatric#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13993, encryptionId=766713993a1, topicName=Pediatric)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jun 20 07:24:00 CST 2013, time=2013-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636576, encodeId=2cc116365e65b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 08 17:24:00 CST 2012, time=2012-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725454, encodeId=b1aa1e2545455, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jul 17 22:24:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578640, encodeId=d69615e864080, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sun Sep 30 05:24:00 CST 2012, time=2012-09-30, status=1, ipAttribution=)]

相关威廉亚洲官网

JAMA:鱼油或能延长移植物畅通时间

近日,刊登在《美国医学会杂志》(JAMA)上的一项新研究披露,在血管通路中使用新型合成型动静脉移植物(一种嫁接在动静脉之间的合成物管子)的血液透析患者,每日摄取鱼油,12个月内对移植物通畅性丧失比例有一定影响,但是该比例不会显著降低。鱼油是鱼体内的全部油类物质的统称,它包括体油、肝油和脑油。 研究报告指出:“理想的血液透析需要可靠的血管通路,包括动静脉瘘(用手术方法在动脉与静脉间创建一种连接)、